NCT01120236 is a phase II clinical trial led by NCI to study whether specific miRNA expression profiles are correlated with PSA responses and/or circulating tumor cell (CTC) counts after metastatic PCa patients are treated with androgen deprivation therapy and cixutumumab for 28 weeks. Here, KLK3 is linked to posterior cortical atrophy.